Glenmark Pharmaceuticals has informed that it attached media release on October 26, 2021 titled ‘Glenmark becomes the first company to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India’.
The above information is a part of company’s filings submitted to BSE.